Scott M. Wasserman
Scott M. Wasserman publishes mostly in Surgery, Immunology and Economics and Econometrics, on topics such as Lipoproteins and Cardiovascular Health, Atherosclerosis and Cardiovascular Diseases and Pharmaceutical Economics and Policy.
- World rank
- #70,054 of 7,710,434 ranked researchers
- Rank in United States
- #27,059 of 1,627,098
- Works
- 177
- Citations
- 26k
- Citations per work
- 149.4
What does Scott M. Wasserman research?
Scott M. Wasserman's work is mostly in Medicine (44%), Immunology and Microbiology (10%), Economics, Econometrics and Finance (7%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences7944.5%
- Medicine7944.5%
- Everything else5732.1%
- Life Sciences2916.2%
- Social Sciences137.2%
- 1Surgery31% of their works
- 2Immunology10% of their works
- 3Economics and Econometrics7% of their works
- 4Cardiology and Cardiovascular Medicine7% of their works
- 5Cancer Research6% of their works
- 6Endocrinology, Diabetes and Metabolism6% of their works
Research topics
- Lipoproteins and Cardiovascular Health
- Atherosclerosis and Cardiovascular Diseases
- Pharmaceutical Economics and Policy
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Biosimilars and Bioanalytical Methods
- Protease and Inhibitor Mechanisms
- Cancer, Lipids, and Metabolism
- Heart Failure Treatment and Management
Which keywords describe Scott M. Wasserman's research?
The keywords of their largest research topics: Statins, Cardiovascular Disease Prevention, Cholesterol-lowering, Atherosclerosis, Cholesterol, Cardiovascular Disease, Immune Response and Inflammation.
- Heart Failure
- Tissue Inhibitors of Metalloproteinases
- Lipid Metabolism
- Immunogenicity
- Metabolic Syndrome
- Generic Drugs
- Inflammation
- Cardiovascular Disease
- Atherosclerosis
- Cardiovascular Disease Prevention
- Statins
- Cholesterol-lowering
- Cholesterol
- Immune Response
- Drug Development Costs
- Diabetes
- Biosimilars
- Fatty Acid Synthase
- Matrix Metalloproteinases
- Guidelines
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 20 words, with their numbers
- Statins1362 topics
- Cardiovascular Disease Prevention1221 topic
- Cholesterol-lowering1221 topic
- Atherosclerosis442 topics
- Cholesterol322 topics
- Cardiovascular Disease282 topics
- Immune Response261 topic
- Inflammation261 topic
- Drug Development Costs231 topic
- Generic Drugs231 topic
- Diabetes181 topic
- Metabolic Syndrome181 topic
- Biosimilars151 topic
- Immunogenicity151 topic
- Fatty Acid Synthase141 topic
- Lipid Metabolism141 topic
- Matrix Metalloproteinases141 topic
- Tissue Inhibitors of Metalloproteinases141 topic
- Guidelines101 topic
- Heart Failure101 topic
Where does Scott M. Wasserman work?
Scott M. Wasserman's main affiliation in the publication record is Amgen (United States), United States.
How many publications and citations does Scott M. Wasserman have?
OpenAlex counts 177 works and 26,435 citations for Scott M. Wasserman, an h-index of 62, ranking #70,054 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Scott M. Wasserman. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.